Ernexa Therapeutics News and Activities

Ernexa Therapeutics is a company listed under the stock ticker ERNA (US).

Acquisition, funding and merger involving Ernexa Therapeutics.

• The new name of Eterna Therapeutics is Ernexa Therapeutics. (posted on March 26 2025).

View the org chart displaying its 5 main executives

Most searched biographies at Ernexa Therapeutics

• Sanjeev Luther, Chief Executive Officer and Director
• Robert Pierce, Chief Scientific Officer
• Michelle Matzko, Senior Vice President, Clinical Development

Popular executive movements at Ernexa Therapeutics

• Michelle Matzko has joined the company as Senior Vice President, Clinical Development  (posted on June 29 2026).
• Sandra Gurrola, Senior Vice President, Finance, will leave the company on Jul. 3, 2026  (posted on June 29 2026).

Create your alert
to follow the executive moves at Ernexa Therapeutics.

Ernexa Therapeutics has 2,426 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• The new name of ChemoTech is Neem’s Hill. (posted on July 14 2026).
• MindRank has just announced a $52 Million fundraising (posted on July 14 2026).
• Chemomab and Scipher Medicine have announced they will merge  (posted on July 13 2026)..

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by Ernexa Therapeutics

• Newsroom – Eterna Therapeutics Inc.Eterna
• In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Dr. Matt Angel, CEO Eterna Therapeutics | Your Source for the Hottest Growth Stock Research and News
• Reporter's Notebook: Opening Day at the J.P. Morgan Healthcare Conference
• Partnership to develop novel stem cell lines for CNS disorders, other neuro conditions
• Tapping the potential of mRNA in cellular reprogramming and beyond
• Newsroom – Eterna Therapeutics Inc.Eterna
• Eterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General Counsel – Eterna Therapeutics Inc.Eterna
• Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting – Eterna Therapeutics Inc.Eterna
• Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting – Eterna Therapeutics Inc.Eterna
• Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics – Eterna Therapeutics Inc.Eterna
• View more press releases Close

Social media about Ernexa Therapeutics

• Ernexa Therapeutics on Wikipedia, Google News & Yahoo Finance
• Ernexa Therapeutics on LinkedIn, X (Twitter) & YouTube